Press Releases News Year None202020192018201720162015201420132012 Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) Jan 16, 2018 | Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors Jan 16, 2018 | Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 02, 2018 | Ophthotech Reports Third Quarter 2017 Financial and Operating Results Nov 08, 2017 | Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Oct 30, 2017 | Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases Sep 19, 2017 | Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration Aug 14, 2017 | Ophthotech Reports Second Quarter 2017 Financial and Operating Results Jul 26, 2017 | Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases Jul 26, 2017 | Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017 Jul 21, 2017 | Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) Jan 16, 2018 |
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors Jan 16, 2018 |
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 02, 2018 |
Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Oct 30, 2017 |
Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases Sep 19, 2017 |
Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration Aug 14, 2017 |
Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017 Jul 21, 2017 |
Press Releases News Year None202020192018201720162015201420132012 Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) Jan 16, 2018 | Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors Jan 16, 2018 | Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 02, 2018 | Ophthotech Reports Third Quarter 2017 Financial and Operating Results Nov 08, 2017 | Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Oct 30, 2017 | Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases Sep 19, 2017 | Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration Aug 14, 2017 | Ophthotech Reports Second Quarter 2017 Financial and Operating Results Jul 26, 2017 | Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases Jul 26, 2017 | Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017 Jul 21, 2017 | Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) Jan 16, 2018 |
Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors Jan 16, 2018 |
Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference Jan 02, 2018 |
Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017 Oct 30, 2017 |
Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases Sep 19, 2017 |
Ophthotech Announces Results from Third Phase 3 Trial of Fovista® in Wet Age-Related Macular Degeneration Aug 14, 2017 |
Ophthotech Corporation to Report Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, July 26, 2017 Jul 21, 2017 |
